The Wildbad Kreuth initiative: European current practices and recommendations for optimal use of blood components

被引:6
|
作者
Berger, Karin [1 ]
Klein, Harvey G. [2 ]
Seitz, Rainer [3 ]
Schramm, Wolfgang [1 ]
Spieser, Jean-Marc [4 ]
机构
[1] Univ Hosp Munich, Dept Transfus Med & Hemostasis, D-81377 Munich, Germany
[2] NIH, Warren Grant Magnuson Clin Ctr, Dept Transfus Med, Bethesda, MD 20892 USA
[3] Paul Ehrlich Inst, Div Hematol Transfus Med, D-6070 Langen, Germany
[4] Council Europe, European Directorate Qual Med & HealthCare EDQM, Dept Biol Standardizat, OMCL Network & HealthCare DBO, Strasbourg, France
关键词
Blood; Blood products; Optimal use;
D O I
10.1016/j.biologicals.2011.03.002
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
With the aging population in Europe it is anticipated that the growing demand for blood products will not be met by the estimated supply. Therefore up-to-date recommendations for optimal administration of blood products in hemotherapy are needed. Ten years after the first meeting on optimal use of blood products at Wildbad Kreuth, Germany, a second symposium was organized to convene leading experts from the clinical, regulatory and economic perspective. The aim was to re-evaluate the existing state of hemotherapy, identify areas where further studies are needed, and to provide up-dated recommendations. A preparatory survey by questionnaire concerning guidelines, quality management in clinical use of blood products, provision of products in the individual countries and re-evaluation of the 1999 Wildbad Kreuth recommendations was completed in advance. The second Kreuth Meeting in April 2009 was attended by 110 experts in transfusion medicine, regulators and regulatory authorities from 38 countries. By consensus, 20 new recommendations were adopted. Most of the 1999 recommendations were found to still be valid 10 years later. But their realization and implementation on the levels of clinical practice, regulatory authorities and health policy decision makers is still lagging behind leaving an important task to accomplish. The Kreuth initiative toward optimal use of blood products should continue.
引用
收藏
页码:189 / 193
页数:5
相关论文
共 37 条
  • [21] Current practices in clinical gait analysis in Europe: A comprehensive survey-based study from the European society for movement analysis in adults and children (ESMAC) standard initiative
    Armand, Sephane
    Sawacha, Zimi
    Goudriaan, Marije
    Horsak, Brian
    van der Krogt, Marjolein
    Huenaerts, Catherine
    Daly, Colm
    Kranzl, Andreas
    Boehm, Harald
    Petrarca, Maurizio
    Guiotto, Anna
    Merlo, Andrea
    Spolaor, Fabiola
    Campanini, Isabella
    Cosma, Michela
    Hallemans, Ann
    Horemans, Herwin
    Gasq, David
    Moissenet, Florent
    Assi, Ayman
    Sangeux, Morgan
    GAIT & POSTURE, 2024, 111 : 65 - 74
  • [22] Preferential Use of Bare Metal Over Drug Eluting Stents in Primary Percutaneous Coronary Intervention: Can We Afford Current European Guidelines Recommendations?
    Garcia, Alberto Nunez
    Rodriguez, Javier Botas
    Ayac, Luis A. Inga
    Medina, Roberto Del Castillo
    Marrupe, Lorenzo Hernando
    Adriana, De la Rosa Riestra
    Bello, Javier Alonso
    Cela, Maher Chichakli
    CIRCULATION, 2016, 134
  • [23] Preferential Use of Bare Metal Over Drug Eluting Stents in Primary Percutaneous Coronary Intervention: Can We Afford Current European Guidelines Recommendations?
    Garcia, Alberto Nunez
    Rodriguez, Javier Botas
    Ayac, Luis A. Inga
    Medina, Roberto Del Castillo
    Marrupe, Lorenzo Hernando
    Adriana, De la Rosa Riestra
    Bello, Javier Alonso
    Cela, Maher Chichakli
    CIRCULATION, 2016, 134
  • [24] Workshop: Making optimal use of individual health records for public health monitoring and research in a privacy respecting manner: current developments and best practices
    不详
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2010, 20 : 101 - 101
  • [25] Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members
    Mentre, F.
    Chenel, M.
    Comets, E.
    Grevel, J.
    Hooker, A.
    Karlsson, Mo
    Lavielle, M. O.
    Gueorguieva, I.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2013, 2 (06):
  • [26] Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation:: Joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation
    Rizzo, JD
    Wingard, YR
    Tichelli, A
    Lee, SJ
    Van Lint, MT
    Burns, LJ
    Davies, SM
    Ferrara, JLM
    Socié, G
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 138 - 151
  • [27] Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative
    Rossi, Paolo Giorgi
    Lebeau, Annette
    Canelo-Aybar, Carlos
    Saz-Parkinson, Zuleika
    Quinn, Cecily
    Langendam, Miranda
    Mcgarrigle, Helen
    Warman, Sue
    Rigau, David
    Alonso-Coello, Pablo
    Broeders, Mireille
    Graewingholt, Axel
    Posso, Margarita
    Duffy, Stephen
    Schunemann, Holger J.
    BRITISH JOURNAL OF CANCER, 2021, 124 (09) : 1503 - 1512
  • [28] Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative
    Paolo Giorgi Rossi
    Annette Lebeau
    Carlos Canelo-Aybar
    Zuleika Saz-Parkinson
    Cecily Quinn
    Miranda Langendam
    Helen Mcgarrigle
    Sue Warman
    David Rigau
    Pablo Alonso-Coello
    Mireille Broeders
    Axel Graewingholt
    Margarita Posso
    Stephen Duffy
    Holger J. Schünemann
    British Journal of Cancer, 2021, 124 : 1503 - 1512
  • [29] Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation:: Joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT)
    Rizzo, JD
    Wingard, JR
    Tichelli, A
    Lee, SJ
    Van Lint, MT
    Burns, LJ
    Davies, SM
    Ferrara, JLM
    Socié, G
    BONE MARROW TRANSPLANTATION, 2006, 37 (03) : 249 - 261
  • [30] Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT)
    J D Rizzo
    J R Wingard
    A Tichelli
    S J Lee
    M T Van Lint
    L J Burns
    S M Davies
    J L M Ferrara
    G Socié
    Bone Marrow Transplantation, 2006, 37 : 249 - 261